Evidence map›Paper›PMID 40094997›Full record

ArticleAnalytical and bioanalytical chemistry2025

Metabolite biomarkers of screening neonatal congenital hypothyroidism based on dried blood spot metabolomics.

Xingyu Guo, Feng Suo, Yuting Wang, Di Yu, Yi Wang, Bulian Dong, Lingshan Gou, Xinhui Gan, Benjing Wang, Chaowen Yu and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Analytical and bioanalytical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Xingyu Guo *School of Chemistry, Dalian University of Technology, Dalian, 116024, China.
Feng Suo *Center for Genetic Medicine, Maternity and Child Health Care Hospital Affiliated to Xuzhou Medical University, Xuzhou, 221009, China.
Yuting WangState Key Laboratory of Medical Proteomics, CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, 116023, China.
Di YuState Key Laboratory of Medical Proteomics, CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, 116023, China.
Yi WangCenter for Genetic Medicine, Maternity and Child Health Care Hospital Affiliated to Xuzhou Medical University, Xuzhou, 221009, China.
Bulian DongCenter for Genetic Medicine, Maternity and Child Health Care Hospital Affiliated to Xuzhou Medical University, Xuzhou, 221009, China.
Lingshan GouCenter for Genetic Medicine, Maternity and Child Health Care Hospital Affiliated to Xuzhou Medical University, Xuzhou, 221009, China.
Xinhui GanMaternity and Child Health Care of Zaozhuang, Zaozhuang, 261031, China.
Benjing WangCenter for Reproduction and Genetics, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, 215006, China.
Chaowen YuCenter for Clinical Molecular Medicine & Newborn Screening, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Engineering Research Center of Stem Cell Therapy, Children'S Hospital of Chongqing Medical University, Chongqing, 400014, China.
Xiaoxiang XieMaternity and Child Health Care of Jiujiang, Jiujiang, 332001, China.
Dandan LinghuMaternity and Child Health Care of Yuncheng, Yuncheng, 044000, China.
Xinyu LiuState Key Laboratory of Medical Proteomics, CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, 116023, China. liuxy2012@dicp.ac.cn.ORCID http://orcid.org/0000-0002-0564-7167
Maosheng GuCenter for Genetic Medicine, Maternity and Child Health Care Hospital Affiliated to Xuzhou Medical University, Xuzhou, 221009, China. gumaosheng2007@126.com.ORCID http://orcid.org/0000-0002-6595-9090
Guowang XuState Key Laboratory of Medical Proteomics, CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, 116023, China. xugw@dicp.ac.cn.ORCID http://orcid.org/0000-0003-4298-3554

Funding

National Key Research and Development Program of China 2022YFC3401203National Natural Science Foundation of China 22204164nnovation program of Science and Research from the DICP DICP I202334Strategic Priority Research Program (B) of Chinese Academy of Sciences XDB38020200Youth Innovation Promotion Association CAS 2021186
6 · The paper itself

Abstract

Congenital hypothyroidism (CH) can be detected early during thyroid-stimulating hormone (TSH) screening based on dried blood spot (DBS) samples. However, it falls short in differentiating between neonates with elevated TSH levels and those with CH, which leads to many neonates undergoing secondary diagnosis through venous blood sampling. Metabolomics was used to analyze metabolic alterations in neonates with CH, and identify DBS-based metabolite biomarkers for CH screening to reduce secondary diagnosis. Based on non-targeted metabolomics, the metabolic alterations in neonates with CH were analyzed in a discovery set and novel biomarkers were identified. The results of the discovery set revealed that the metabolic alterations in neonates with CH were primarily in amino acid and lipid metabolism, and identified novel metabolite biomarkers were thyroxine, 2-piperidinone, and PC (14:0/20:4). Then, these biomarkers were validated in a validation set, and the screening performance was still satisfactory. A rapid 3.5-min targeted method for three potential biomarkers was further developed and used to analyze a confirmation set. Analysis of the confirmation set re-validated the reliability of the biomarkers, and a biomarker combinational model equation and an appropriate cutoff value were defined. Each set of DBS samples included neonates with health, hyperthyrotropinemia, and CH. The novel metabolite biomarkers from DBS samples demonstrate significant potential for CH screening in neonates, effectively reducing the requirement associated with secondary diagnosis of mis-screened neonates.

Indexed as

BiomarkersCongenital HypothyroidismDried Blood Spot TestingMetabolomicsNeonatal ScreeningFemaleHumansInfant, NewbornMaleReproducibility of ResultsTandem Mass SpectrometryThyrotropinBiomarkersThyrotropinCongenital hypothyroidismDried blood spotMetabolite biomarkersMetabolomicsNewborn screening

Identifiers

PMID40094997

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.